NT
The startup develops a gene therapy that utilizes adeno-associated virus-based delivery of neural transcription factors to convert astrocytes into neurons, targeting neurodegenerative diseases and neural injuries. This technology enables the restoration of damaged neural tissue, providing a potential therapeutic solution for conditions that currently lack effective treatments.
Updated 3 months ago
Funding
$34.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops a gene therapy that utilizes adeno-associated virus-based delivery of neural transcription factors to convert astrocytes into neurons, targeting neurodegenerative diseases and neural injuries. This technology enables the restoration of damaged neural tissue, providing a potential therapeutic solution for conditions that currently lack effective treatments.